Abstract. Cervical cancer is the seventh most common cancer overall and the third among females. To obtain systematic insight into the protein profile that participates in cervical tumor oncogenesis and improve the current target therapies, iTRAQ labeling and NanoLC-MS/MS analysis were utilized to detect differentially expressed proteins in cervical cancer. As a result, 3,647 proteins were identified, among which the expression levels of 294 proteins in cervical cancer samples were distinct from the paired non-tumor samples. Further validation of the differentially expressed proteins, including G6PD, ALDH3A1, STAT1 and HSPB1, was carried out via qRT-PCR, western blot analysis and tissue microarray. Functional analysis of one of the highly expressed proteins, G6PD, was performed using RNA interference. Attenuated G6PD expression reduced the capacity of HeLa cells to migrate and invade in vitro. Our investigation complemented the understanding of cervical cancer progression. Furthermore, the present study supports the notion that suppressing the expression of G6PD may be a promising strategy in developing novel cancer therapeutic drugs.
Introduction
Cervical tumor is the seventh most common cancer overall and the third among women (1) . Annually, more than 500,000 new cases of invasive cervical carcinoma are diagnosed globally, representing ~10% of all cancers in females. Furthermore, 80% of the cases occur in developing countries and the survival rate is still poor (2) . Although significant advances have been made in cervical cancer diagnosis, late stage diagnosis and poor survival are major challenges. As infection by human papillomavirus (HPV) types 16 and 18 has been shown to be a central causal agent for cervical cancer (3, 4) , consensus panels of the International Agency for Research on Cancer (IARC) and WHO concluded that there is enough justification to evaluate HPV testing as an adjunct to Papanikolaou (Pap) smear screening for cervical cancer (5, 6) . However, due to the lack of knowledge regarding the development and progression of cervical cancer, it still has one of the highest mortality rates among the common malignancies in women. It is urgent to provide insight into the mechanism of cervical cancer, with the expectation of finding more effective and alternative molecular targets for treatment of this disease.
Comparative proteomic analysis provides a comprehensive evaluation of protein expression, and has been widely applied in cancer research (7) . For example, Annexin A2 (ANXA2) was demonstrated as a factor linked to cell transformation and oncogenesis in cervical cancer via two-dimensional electrophoresis (2-DE) and MALDI-TOF mass spectrometric analysis (8) . Based on 2-DE analysis between human cervical squamous cell carcinoma (SCC) and normal cervical tissues, overexpression of cytokeratin-19 was linked to prosoplasia and uncontrolled proliferation of cervical epithelial tissue (9) . In another investigation, differences in the abundance of zinca-2-glycoprotein (ZAG) in serum between endometrial adenocarcinoma patients and cervical tumor patients were examined by 2-DE with silver staining. Moreover, ZAG was identified as an indicator linked to the development of cachexia (10) . However, considerable inter-gel variation, low sensitivity and excessive time/labor costs are common disadvantages with the standard 2-DE approach (7, 11) .
Isotope-based quantitative proteomics have been employed in analyzing post-translational modifications or discovering biomarkers. Compared to other isotope-based technologies, such as isotope-coded affinity tags (ICAT), 18O and stable isotope labeling with amino acids in cell culture (SILAC) (12) (13) (14) , the isobaric tags for relative and absolute quantitation (iTRAQ) method is deemed to be outstanding, since it can analyze multiple samples in one experiment for simultaneous analysis. In the present study, iTRAQ labeling coupled with high resolution mass spectrometry was carried out to detect the difference in proteins between cervical cancer and non-cancer samples. We expected to find host proteins iTRAQ-based quantitative proteomic analysis of cervical cancer iTRAQ labeling and peptide fractionation. Total proteins (100 µg) extracted from each sample were denatured, cysteine blocked, and digested as described in the standard protocol of the iTRAQ kit (AB Sciex, Framingham, MA, USA). Pooled non-tumor samples were labeled with iTRAQ tags 113 and 115, and tags 114 and 116 were used to label pooled cervical tumor samples. The labeled peptides were pooled in 1:1:1:1 ratio and lyophilized. The mixture was separated with an LC-30 high performance liquid chromatography system (Shimadzu, Kyoto, Japan) by gradient elution. The detailed procedures are shown in Table I . Ten fractions were collected and lyophilized for further analysis.
NanoLC-2D-TripleTOF 5600 analysis. A Triple TOF 5600 system coupled to an Eksigent NanoLC-2D system (AB Sciex) was used for protein identification and quantization. Each fraction was separated in a 2-h gradient elution by the NanoLC-2D system (Table I ). The mass spectrometer was set in the positive ion mode at a mass range of 350-1,500 m/z, with a 0.25-sec accumulation time, followed by information-dependent acquisition (IDA). The top 30 precursor ions within each cycle were automatically selected for fragmentation, with each MS/MS spectrum accumulated for 0.1 sec (100-1,500 m/z). ProteinPilot v.4.5 software (AB Sciex) was used for data search against the UniProt database. The standard searching parameters and false discovery rate analysis were set. A threshold of confidence >99% and a local false discovery rate (FDR) of <1% were used for both protein identification and quantitative analysis. More than 2 unique peptides were required for protein identification. P-values <0.01 were required for relative quantification. The PeakView 1.1 software was used to extract ion chromatograms.
Quantitative real time-PCR analysis (qRT-PCR).
Total RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany), and 100 ng of total RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara, Dalian, China). qRT-PCR assays were performed on an ABI 7900HT system with TaqMan kits. Primers for G6PD (Hs00166169-m1), STAT1 (Hs01014007_m1), HSPB1 (Hs03044127_g1), DCN (Hs00466796_CE), ALDH3A1 (Hs00964880_m1), EPX (Hs00417510_CE), PRG3 (Hs00196082_m1), OGN (Hs00247901_m1), CRNN (Hs00211833_m1), AGR2 (Hs00356521_m1), ORM2 (Hs00301996_CE) and GAPDH (Hs02758991_g1) were used. Each sample was run in triplicate, and all reactions were performed at least twice. The 2 -∆∆CT method was used for data analysis. the samples. Bands were detected with an ECL detection system (Amersham Biosciences). Each sample was analyzed at least twice. Detailed procedure of experiments was described in a previous study (15) .
Immunohistochemistry (IHC) and tissue microarray.
The tissue microarrays (CR802) were purchased from US Biomax, Inc. (Rockville, MD, USA) to detect G6PD, STAT1, HSPB1 and ALDH3A1 in cores from 40 cervical tumor tissues and 40 non-tumor tissues, antibodies against G6PD (1:90), STAT1 (1:200), HSPB1 (1:250) and ALDH3A1 (1:200) were added and incubated overnight at 4˚C. Detection was performed with the Envision/horseradish peroxidase system (DakoCytomation, Glostrup, Denmark). Semi-quantification of protein expression was defined by scoring criteria. The positive cells (%) and staining intensity (scale 0-3) were checked, which were then multiplied to yield a score ranging from 0 to 300. To maintain consistency, the same qualified pathologist gave interpretations for all IHC data.
Wound healing and invasion assay. G6PD-specific (50 nM) siRNAHSS103891, HSS103892 and HSS103893 (Invitrogen, Carlsbad, CA, USA) or negative control siRNA (12935-400; Invitrogen) were transfected into HeLa cells (10 5 cell/well). After 48 h, wound healing and invasion experiments were performed on 6-well plates seeded with HeLa cells. After the cells reached confluency, a 200 µl pipette tip was used to incise the cell monolayer. The debris was rinsed away and removed. The extent of gap closure was monitored and photographed under a microscope up to 24 h. The invasion assays were performed using a Cell Invasion Assay kit (Cell Biolabs, San Diego, CA, USA), following the manufacturer's instructions. After 24 h, the number of cells that invaded and attached to the bottom chamber was measured by CyQuant GR fluorescent dye (560 nm).
Statistical analyses. Statistical analyses were performed by SPSS software v13.0 using the Student'st-test, Mann-Whitney U-test, χ 2 test or Spearman's rank correlation analysis. A P-value <0.05 was considered statistically significant. All tests of significance were two-tailed.
Results
Functional profiles of differentially expressed proteins in cervical tumors. In total, 3,647 proteins were identified with 1% global FDR from fit in cervical cancer following a workflow shown in Fig. 1 . For subsequent relative quantification analysis, a cut-off of 1.3-fold change, up or down, was applied to all iTRAQ ratios to minimize false positives when identifying proteins as overerexpressed or downregulated. This process is widely adopted in other proteomics investigations (16) (17) (18) (19) . Accordingly, 294 proteins were identified as differentially expressed in pooled cervical tumor tissues comparing to non-tumor tissues, including 130 upregulated and 164 downregulated proteins. The top 30 upregulated proteins and top 30 downregulated proteins were listed in Table II .
To obtain the functional characteristics of proteins associated with cervical carcinoma oncogenesis, we classified the 294 proteins using Protein Analysis through Evolutionary Relationships Classification System (PANTHER, www. pantherdb.org). Twelve biological processes are involved, with 55.0% of the proteins participating in metabolic processes, followed by cellular processes (37.1%) and developmental processes (19.4%). According to molecular function, the proteins were divided into 10 categories, including catalytic activity (37.8%), binding activity (32.0%) and structural molecule activity (19.4%). The 294 proteins were grouped into 27 protein classes, including cytoskeletal protein (14.7%), hydrolase (12.9%) and nucleic acid binding proteins (10.4%). A total of 63 signaling pathways were associated, with inte- 3.39E-10 decarboxylating grin signaling pathway (3.2%), blood coagulation (2.9%) and inflammation mediated by chemokine and cytokine signaling pathway (2.2%) at the top of the list (Fig. 2) .
Validation of altered expression levels of proteins.
The iTRAQ study results were further validated by qRT-PCR and western blot analyses. Fig. 3A shows the relative mRNA levels of selected differentially expressed proteins in the cervical tumor tissues, compared to those in the paired non-tumor tissues. The mRNA levels of G6PD, HSPB1, STAT1, ALDH3A1, FSCN1, EPX and PRG3 were found to be upregulated, whereas the levels of DCN, OGN, CRNN, AGR2 and ORM2 were downregulated. The upregulation of protein levels of G6PD, HSPB1, STAT1, ALDH3A1 and FSCN1 were subsequently detected by western blot analysis (Fig. 3B ). This trend matched that observed in the iTRAQ method.
Expression of G6PD, HSPB1, STAT1 and ALDH3A1 in tissue array.
The clinical relevance of G6PD, HSPB1, STAT1 and ALDH3A1 in cervical cancer was assessed by IHC analysis (Fig. 4) . A tissue microarray including 40 cervical cancer tissues and 40 matched or unmatched non-cancer cervical tissues was analyzed. As a result, cervical cancer samples showed significantly higher levels of G6PD, HSPB1, STAT1 and ALDH3A1 than those in controls. Moreover, G6PD expression was detected in 100% (40/40) of cervical cancer samples, compared to 45% (18/40) in controls. The staining intensity of G6PD in cervical cancer cells was much stronger than that in control epithelial cells. Similar trends were observed in the IHC analysis of HSPB1, STAT1 and ALDH3A1.
G6PD knockdown compromised HeLa cells' invasion and migration.
The dramatic increase of G6PD in cervical cancer suggested that G6PD not only contributes to the biosynthesis of cervical cancer cells, but also is crucial for their malignancy. To test this hypothesis, HeLa, a human cervical cancer cell line, was tested with an RNA interference assay. G6PD expression in HeLa cells was initially silenced by transfection of G6PD-specific siRNAs (Fig. 5A ). G6PD-silenced HeLa cells and control cells were then subjected to invasion and migration assays. Invasion capacity of G6PD-silenced cells was inhibited by 30-40% when compared to that of the control cells (P<0.01) (Fig. 5B) . The readout of the scratch wound repair assays was reduced by 55-65% in G6PD-silenced cells when compared to that of the control cells (P<0.01) (Fig. 5C ).
Our results supported the notion that G6PD may be an effective target in cervical cancer treatment.
Discussion
Cervical cancer remains one of the leading causes of death among women throughout the world. The morbidity and death rates remain frustratingly high in spite of several emerging biomarkers for diagnosis. Discovery of novel factors that are related to the biology of cervical carcinoma is an urgent task for improving current treatment strategies and prognosis of the disease.
In the present study, we identified proteins differentially expressed between tumor and non-tumor cervical tissues via the iTRAQ proteomics approach. Verification studies using Table II The ratios indicated relative protein levels in cervical cancer tissues compared to those in paired non-cancer tissues.
b P values were calculated using the Paragon Algorithm in the ProteinPilot software.
qRT-PCR, immunoblot and IHC assays confirmed that the expressions of G6PD, STAT1, ALDH3A1 and HSPB1 were, indeed, significantly increased in tumor tissues. Functional studies indicated that G6PD tends to act on migration and invasion of cervical cancer cells. Our findings revealed that the iTRAQ method for large-scale protein quantification is amenable to high throughput processes and credible, and some novel proteins uncovered here may serve as potential targets for cervical tumor treatment. G6PD, as the first and rate-limiting enzyme in the ubiquitous pentose phosphate pathway (PPP) (20) , participates in biological processes of various cancers (21) (22) (23) . Through PPP, the biosynthesis and rapid proliferation of tumor cells are supported (24, 25) . In non-tumor cells, G6PD binds with p53 protein to prevent it from forming the active dimer (26) . This process, however, inhibits PPP by quenching functional G6PD (27) . Notably, this inhibition of G6PD by p53 does not exist in tumor cells, because mutant p53 loses its inhibitory effect on G6PD, and, thus, results in elevated PPP glucose flux, which ultimately enhances glucose consumption and promotes tumor cell biosynthesis (26) . In other words, G6PD motivates cancer cell proliferation and contributes to tumorigenesis by increasing PPP glucose flux. Since the relationship between G6PD and cervical cancer was not well investigated previously, we examined the effect of G6PD proteins on HeLa cells. As a consequence, the invasion and migration capabilities of HeLa cells were decreased in vitro when G6PD expression was suppressed. Our results, together with findings of other groups, indicate that the suppression of G6PD expression may be beneficial in cervical cancer treatment. Another markedly upregulated protein in cervical cancer found in the present study was STAT1, a member of STAT protein family. STAT1 was noted to be critical in controlling cell cycle progression and apoptosis. Hix et al (28) studied STAT1 effects by injecting mouse mammary carcinoma cell TM40D with/without ectopic STAT1 into the mammary fat pads of BALB/c mice and observed that the growth and aggressiveness of TM40D-STAT1 cells were dramatically enhanced, when compared to those of regular TM40D cells. Conversely, the growth of TM40D cells was significantly delayed when STAT1 was knocked down. Further studies demonstrated that STAT1 promoted breast cancer by increasing interleukin-13 (IL-13), transforming growth factor β (TGFβ) and tumor necrosis factor α (TNFα). These factors could inhibit antitumor immune responses by recruiting and stimulating associated cells (29) . In addition, Rajkumar et al (30) found that STAT1 rose in early cervical intraepithelial neoplasia (CIN1/2), dropped in CIN3/CIS, and was dramatically upregulated in invasive cervical carcinoma, demonstrating that STAT1 may harbor double roles in HPV infection and cervical tumori- genesis, specifically a protective role in the early phase and an oncogenic role in the invasive stages of the tumor. Further investigation is required to determine the roles of STAT1 in cervical tumorigenesis.
HSPB1 protein, also named heat shock protein 27 (Hsp27), belongs to the emerging 'survival protein' family (31) (32) (33) . The expression of HSPB1 is involved in cell proliferation (34) and apoptosis (35) and is associated with poor prognosis in various tumors (34, 36) . The inhibitor of HSPB1, OGX-427, a secondgeneration antisense oligonucleotide of HSPB1, downregulated the levels of HSPB1 and induced the apoptosis of cancer cells (37) . This occurs via the disruption of the interaction of HSPB1 with cytochrome c (cytc), procaspases-9 and -3 (35) . Thus, the attenuation of the expression of HSPB1 gene was considered as a new therapeutic strategy. Moreover, McCollum et al (38) were able to successfully make prostate cancer cells more sensitive to the antitumor drug 17-allylamino-demethoxygeldanamycin by employing small-interfering RNA (siRNA) against HSPB1. Together, accumulating evidence supports the notion that upregulation of HSPB1 stimulates cancer cell proliferation, whereas its downregulation results in the inhibition of tumor progression.
ALDH3A1 proteins identified in the present study has been suggested involved in tumor progression, but not implicated in cervical cancer. The aldehyde dehydrogenase superfamily member ALDH3A1 belongs to the phase II group of drugmetabolizing enzymes and plays key roles in numerous biological processes, such as cell survival and growth (39) . Upregulation of ALDH3A1 is frequent in tumor-derived cell lines and neoplastic tissues (40) . By removing lipid peroxidation products, the overexpression of ALDH3A1 promoted the growth of rat hepatoma cells (41) . In contrast, a reduced expression of ALDH3A1 inhibited the growth of cancer cells tested in lung tumor cell line A549 via activating peroxisome proliferator activated receptor γ (PPARγ), which inhibits NF-κB activity (42) . These findings are consistent with our observations made in cervical carcinoma and suggested that ALDH3A1 may be a promising candidate target of cervical cancer therapy.
In summary, we performed a non-targeted proteomics study to profile differentially expressed proteins in cervical cancer. The proteins uncovered, as well as studied, in the present study may serve as potential targets for cervical cancer research and treatment.
